Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Allopurinol Maintenance Study for Bipolar Disorder
NCT00732251 · Cedars-Sinai Medical Center · PHASE4 · terminated · last registry update 2019-10-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The outpatient area of the department of psychiatry at CSMC closed.” | – | Registry record, Cedars-Sinai Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XDH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-29Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Infusion of Treg (NCT02991898)
- 2020-08-14Results posted on the registry: University of Wisconsin, Madison, Losartan + Allopurinol (NCT01637623)
- 2020-07-24Results posted on the registry: Masonic Cancer Center, University of Minnesota, Infusion of Treg (NCT02991898)
- 2020-06-23Results posted on the registry: University of California, San Francisco, Allopurinol (NCT02956278)
- 2020-04-30Phase 3 first posted: Ministry of Health, Brazil, Allopurinol 300 MG + Placebo oral tablet (NCT04368819)
- 2020-02-26Results posted on the registry: University of Alabama at Birmingham, Allopurinol + Placebo (NCT02038179)
- 2020-01-31Results posted on the registry: M.D. Anderson Cancer Center, Rasburicase + Allopurinol (NCT01200485)
- 2020-01-27Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Fludarabine (NCT00899431)
- 2020-01-27Also stopped (terminated): M.D. Anderson Cancer Center, Lenalidomide + Fludarabine (NCT00899431)
- 2020-01-10Results posted on the registry: AstraZeneca, Verinurad 9 mg+Febuxostat 80 mg + Placebo (NCT03118739)
- 2020-01-03Phase 3 first posted: dr. M.J.N.L. Benders, Allopurinol + Mannitol (NCT04217421)
- 2019-12-16Results posted on the registry: University of California, San Diego, Febuxostat (NCT01472692)
- 2019-11-12Results posted on the registry: University of Alabama at Birmingham, a drug against XDH (NCT02790463)
- 2019-10-15Results posted on the registry: Roberto S Kalil, allopurinol or placebo (NCT01332799)
- 2019-10-15Also stopped (terminated): Roberto S Kalil, allopurinol or placebo (NCT01332799)
- 2019-09-24Results posted on the registry: AstraZeneca, RDEA3170 + Allopurinol (NCT02078219)
- 2019-08-12Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR4640 dose1 + SHR4640 dose2 (NCT04052932)
- 2019-08-07Results posted on the registry: University of South Florida, Febuxostat + Colchicine (NCT01112982)
- 2019-07-18Results posted on the registry: AstraZeneca, Verinurad + Febuxostat (NCT03316131)
- 2019-07-09Phase 3 first posted: Instituto Nacional de Cardiologia Ignacio Chavez, Allopurinol Pill (NCT04012294)
- 2019-06-21Results posted on the registry: Menarini International Operations Luxembourg SA, Febuxostat 80/120mg/day + Allopurinol 100 up to 600mg/day (NCT02500641)
- 2019-04-17Also stopped (withdrawn): University of Missouri-Columbia, Allopurinol (NCT03076684)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision